Sapin H1, García-Pérez LE2, Norrbacka K3, Giorgino F4, Guerci B5, Aigner U6, Orsini Federici M7, Gentilella R8, Heitmann E9, Jung H9, Rosilio M10, Boye K11
1Lilly France SAS, Neuilly Sur Seine , France, 2Lilly, S.A., Alcobendas, Spain, 3Eli Lilly and Company, Helsinki, Finland, 4University of Bari Aldo Moro, Bari, Italy, 5Hôpital Brabois Adultes, CHRU de Nancy, France, 6Versdias GmbH, Sulzbach-Rosenberg, Germany, 7Eli Lilly Company Italia SpA, Florence, Italy, 8Former employee of Eli Lilly Company Italia SpA, Florence, Italy, 9Lilly Deutschland GmbH, Bad Homburg, Germany, 10Lilly France SAS, Neuilly Sur Seine, France, 11Eli Lilly and Company, Greenwood, IN, USA
OBJECTIVES: The first injectable therapy usually recommended for type 2 diabetes (T2D) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). Although randomized clinical trials are the standard for efficacy and safety assessments, observational studies may help to better understand the GLP‑1 RA use in clinical practice. This abstract presents the baseline characteristics of patients enrolled in participating countries (France, Germany, Italy) of TROPHIES study. METHODS: TROPHIES is a 24-month, prospective, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with dulaglutide or liraglutide. At baseline, we assessed demographics, T2D duration, HbA1c levels, reported HbA1c targets and pre-existing diabetes-related diagnoses. Analyses were descriptive in nature. RESULTS: To date, we have analyzed data from 2065 patients (France: 342 and 260; Germany: 365 and 363, Italy: 382 and 353 patients for dulaglutide or liraglutide, respectively). In patients initiating dulaglutide or liraglutide, mean age (years) was 57.4 and 58.8 in France, 57.9 and 56.8 in Germany and 61.2 and 62.5 in Italy, respectively. BMI (kg/m2) for patients in France was 33.1 (dulaglutide) and 33.7 (liraglutide), it was 35.7 (dulaglutide) and 36.2 (liraglutide) in Germany and 32.6 (dulaglutide) and 32.4 (liraglutide) in Italy. Mean baseline HbA1c levels were similar across all three countries and exceeded mean reported HbA1c targets. In patients initiating dulaglutide or liraglutide, macrovascular diabetes‑related conditions were reported in 4.1% and 16.9% in France, 6.3% and 5.5% in Germany and 13.6% and 13.6% in Italy, respectively. CONCLUSIONS: In patients from all three countries, mean BMI reflected obesity. Baseline HbA1c levels exceeding the reported targets justifies treatment justification with a GLP-1 RA. Variations in patients’ baseline characteristics across countries may be due to country‑specific clinical guidelines and reimbursement policies. Thus, this study provides insight into the profiles of patients being prescribed dulaglutide or liraglutide in these countries.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark